Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND007 in idiopathic pulmonary fibrosis
NCT07359963Phase 1Not yet recruiting
- Sponsor
- Regend Therapeutics
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of REGEND-007 in idiopathic pulmonary fibrosis (IPF), sponsored by Regend Therapeutics. Primary endpoint: Adverse Events at 12 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
REGEND-007
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07359963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359963.